Anti-ceramide antibodies
AssigneesMemorial Sloan Kettering Cancer Center, Ceramide Therapeutics
InventorsJimmy Rotolo, Richard Kolesnick
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.
Claims13
A method of inhibiting apoptosis in a subject suffering from graft versus host disease (GvHD), radiation disease, or GI syndrome, comprising administering to the subject a therapeutically effective amount of an anti-ceramide antibody or antigen-binding fragment comprising a variable heavy chain (VH) and a variable light chain (VL), wherein
- the VH comprises a heavy chain variable region CDR1 comprising the sequence GYTFTDHTIH (SEQ ID NO:
- 1), a heavy chain variable region CDR2 comprising the sequence YNYPRDGSTKYNEKFKG (SEQ ID NO:
- 2), and a heavy chain variable region CDR3 comprising the sequence GFITTVVPSAY (SEQ ID NO:
- 3), and
- the VL comprises a light chain variable region CDR1 comprising the sequence RASKSISKYLA (SEQ ID NO:
- 4), a light chain variable region CDR2 comprising the sequence SGSTLQS (SEQ ID NO:
- 5), and a light chain variable region CDR3 comprising the sequence QQHNEYPWT (SEQ ID NO:
- 6).
A method for mitigating apoptosis in a subject with GI syndrome comprising:
- administering to the subject, after the subject is exposed to penetrating radiation, an effective amount of an anti-ceramide antibody or antigen binding fragment comprising a variable heavy chain (VH) and a variable light chain (VL), wherein
- the VH comprises a heavy chain variable region CDR1 comprising the sequence GYTFTDHTIH (SEQ ID NO:
- 1), a heavy chain variable region CDR2 comprising the sequence YNYPRDGSTKYNEKFKG (SEQ ID NO:
- 2), and a heavy chain variable region CDR3 comprising the sequence GFITTVVPSAY (SEQ ID NO:
- 3), and
- the VL comprises a light chain variable region CDR1 comprising the sequence RASKSISKYLA (SEQ ID NO:
- 4), a light chain variable region CDR2 comprising the sequence SGSTLQS (SEQ ID NO:
- 5), and a light chain variable region CDR3 comprising the sequence QQHNEYPWT (SEQ ID NO:
- 6).
A method for inhibiting apoptosis in a subject with GvHD comprising:
- administering to the subject, either before the subject receives a transplant or after the subject receives a transplant prior to the onset of GvHD, an effective amount of an anti-ceramide antibody or antigen binding fragment comprising a variable heavy chain (VH) and a variable light chain (VL), wherein
- the VH comprises a heavy chain variable region CDR1 comprising the sequence GYTFTDHTIH (SEQ ID NO:
- 1), a heavy chain variable region CDR2 comprising the sequence YNYPRDGSTKYNEKFKG (SEQ ID NO:
- 2), and a heavy chain variable region CDR3 comprising the sequence GFITTVVPSAY (SEQ ID NO:
- 3), and
- the VL comprises a light chain variable region CDR1 comprising the sequence RASKSISKYLA (SEQ ID NO:
- 4), a light chain variable region CDR2 comprising the sequence SGSTLQS (SEQ ID NO:
- 5), and a light chain variable region CDR3 comprising the sequence QQHNEYPWT (SEQ ID NO:
- 6).
Dependencies are inferred from the claim text.